



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Case No. 04-105-A (400/149))

In the Application of:

James McSwiggen

Serial No.: 10/824,036

Filing Date: April 14, 2004

For: RNA INTERFERENCE MEDIATED
TREATMENT OF POLYGLUTAMINE
(POLYQ) REPEAT EXPANSION DISEASES
USING SHORT INTERFERING NUCLEIC
ACID (siNA)

Examiner: TBD

Group Art Unit: 1645

Confirmation No.: 6045

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Sir:

TRANSMITTAL LETTER

In regard to the above identified application:

1. We are transmitting herewith the attached papers for the above identified new patent application:

- ☒ Second Supplemental Information Disclosure Statement;
☒ Second Supplemental Information Disclosure Statement (IDS) PTO-1449 Form; and
☒ Return Receipt Postcard.

2. With respect to additional fees, no additional fee is required.

3. GENERAL AUTHORIZATION: Please charge any additional fees or credit overpayment to Deposit Account No. 13-2490. A duplicate copy of this sheet is enclosed.

4. CERTIFICATE OF MAILING UNDER 37 CFR § 1.8: The undersigned hereby certifies that this Transmittal Letter and the paper, as described in paragraph 1 hereinabove, are being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450 on July 14 2005.

By :

Anita J. Terpstra
Reg. No. 47,132

McDONNELL BOEHNNEN HULBERT & BERGHOFF LLP
300 SOUTH WACKER DRIVE
CHICAGO, ILLINOIS 60606
TELEPHONE (312) 913-0001
FACSIMILE: (312) 913-0002



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Case No. 04-105-A (400/149))

PATENT

In the Application of:)	
)	
James McSwiggen)	
)	Examiner: TBD
Serial No.: 10/824,036)	
)	Group Art Unit: TBD
Filing Date: April 14, 2004)	
)	Confirmation No.: 6045
For: RNA INTERFERENCE MEDIATED)	
TREATMENT OF POLYGLUTAMINE)	
(POLYQ) REPEAT EXPANSION DISEASES)	
USING SHORT INTERFERING NUCLEIC)	
ACID (siNA))	

SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. Section 1.97 - 1.99, the Applicant wishes to make the following references of record in the above-identified application. This Information Disclosure Statement is in compliance with the continuing duty of candor as set forth in 37 C.F.R. Section 1.56. A partial recitation of the priority claim is as follows. This application is a continuation-in-part of U.S. Patent Application No. 10/783,128, filed February 20, 2004, which is a continuation-in-part of U.S. Patent Application No. 10/757,803, filed January 14, 2004, which is a continuation-in-part of U.S. Patent Application No. 10/720,448, filed November 24, 2003, which is a continuation-in-part of U.S. Patent Application No. 10/693,059, filed October 23, 2003, which is a continuation-in-part of U.S. Patent Application No. 10/444,853, filed May 23, 2003 and a continuation-in-part of 10/652,791, filed August 29, 2003, which is a continuation of 10/422,704, filed April 24, 2003, which is a continuation of U.S. Patent Application No. 10/417,012, filed April 16, 2003. This application is also a continuation-in-part of US Patent Application No. 10/427,160, filed April 30, 2003. All of the applications recited herein are relied upon for an earlier filing date under 35 U.S.C. § 120.

In accordance with Rule 37 CFR §1.98(d), those references marked with an "*" have been previously cited and submitted to the Patent and Trademark Office with the prior applications. All references cited are also listed in the PTO-1449 form enclosed herewith.

The Office has waived the requirement under 37 CFR 1.98 (a)(2)(i) for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC § 371 after June 30, 2003. In accordance with this waiver, cited U.S. patents and U.S. patent application publications are not enclosed.

This statement is not a representation that the listed references have effective dates early enough to be "prior art" within the meaning of 35 U.S.C. Section 102 or Section 103.

Applicants do not believe any fee is due with this submission. If this belief is in error and the Patent Office determines that the fee prescribed in the relevant portion of 37 C.F.R. Section 1.97 is applicable, the undersigned attorney by his signature hereby authorizes any such fee to be debited from Deposit Account 13-2490.

Respectfully submitted,

McDonnell Boehnen Hulbert & Berghoff LLP

Date: July 14 2005

By: 

Anita J. Terpstra
Reg. No. 47,132

McDonnell Boehnen Hulbert & Berghoff LLP
300 South Wacker Drive, 32nd Floor
Chicago, IL 60606
Telephone: 312-913-0001
Facsimile: 312-913-0002

FORM PTO-1449
(Rev. 2-32)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

04-105-A
(400/1149)

Serial No.

10/824,036



**SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use several sheets if necessary)

Applicant:

James McSwiggen

Filing Date:

April 14, 2004

Group:

1645

U.S. PATENT APPLICATION DOCUMENTS

Examiner Initial		Document Number	Filing Date	Name	Class	Subclass	Publication Date if Appropriate
.	*	US 2003/0190635	10/2003	McSwiggen et al.			
	*	US 2003/0206887	11/2003	Morrissey et al.			

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
	*	1325955	07/09/03	EP (Klippel-Giese et al.)				
	*	08208687	08/1996	JP (Hotoda et al.)				
	*	95/04142	02/09/95	WO (Robinson)				
	*	01/097850	12/27/01	WO (Siemeister et al.)				
	*	02/07747	01/31/02	WO (King)				
	*	02/10378	02/07/02	WO (Cowser et al.)				
	*	02/096927	12/05/02	WO (Escobedo et al.)				
	*	03/068797	08/21/03	WO (Rossi et al.)				
	*	03/070910	08/28/03	WO (McSwiggen et al.)				

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449
(Rev. 2-32)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

04-105-A
(400/1149)

Serial No.

10/824,036

**SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use several sheets if necessary)

Applicant:

James McSwiggen

Filing Date:

April 14, 2004

Group:

1645

*	03/080638	10/02/03	WO (Lacasse et al.)				
*	04/043977	05/27/04	WO (Prakush et al.)				
*	04/047872	06/10/04	WO (Kaemmerer)				
*	04/072261	08/26/04	WO (Li et al.)				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).

*	Anderson et al., "Bispecific Short Hairpin siRNA Constructs Targeted to CD4, CXCR4, and CCR5 Confer HIV-1 Resistance," <i>Oligonucleotides</i> , 13:303-312 (2003)
*	Bayard et al., "Increased stability and antiviral activity of 2'-O-phosphoglycerol derivatives of (2'-5')oligo(adenylate)," <i>Eur. J. Biochem.</i> , 142(29):291-298 (1984)
*	International Search Report for PCT/US2004/016390 mailed March 31, 2005

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.